Ajman Specialty General Hospital

Mallinckrodt Completes Financial Restructuring and Irish Examinership Proceedings and Emerges From Chapter 11

Retrieved on: 
Tuesday, November 14, 2023
EBITDA, Food and Drug Administration, Corporation, Independent monitoring board, Food, New Board, LLP, Chairperson, Silver Point Capital, Patient, FDA, Specialty, Trust, Latham & Watkins, Growth, Guggenheim Partners, The Company, Adrenocorticotropic hormone (medication), AlixPartners, Alpha Metallurgical Resources, Pharmaceutical industry, Management, Mallinckrodt, Ajman Specialty General Hospital

DUBLIN, Nov. 14, 2023 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has completed its financial restructuring, emerged from Chapter 11 following an expedited court-supervised process and completed the Irish Examinership Proceedings.

Key Points: 
  • DUBLIN, Nov. 14, 2023 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has completed its financial restructuring, emerged from Chapter 11 following an expedited court-supervised process and completed the Irish Examinership Proceedings.
  • Supported by an enhanced capital structure, Mallinckrodt will continue to focus on advancing its business across its portfolio and executing on recent and planned product launches.
  • The Company's Specialty Generics segment benefits from vertical integration and high-quality U.S.-based manufacturing plants that have supported strong growth.
  • Latham & Watkins LLP, Wachtell, Lipton, Rosen & Katz, Arthur Cox LLP, Richards, Layton & Finger PA, and Hogan Lovells US LLP served as Mallinckrodt's counsel.

Mallinckrodt Completes Financial Restructuring and Irish Examinership Proceedings and Emerges From Chapter 11

Retrieved on: 
Tuesday, November 14, 2023
EBITDA, Food and Drug Administration, Corporation, Independent monitoring board, Food, New Board, LLP, Chairperson, Silver Point Capital, Patient, FDA, Specialty, Trust, Latham & Watkins, Growth, Guggenheim Partners, The Company, Adrenocorticotropic hormone (medication), AlixPartners, Alpha Metallurgical Resources, Pharmaceutical industry, Management, Mallinckrodt, Ajman Specialty General Hospital

DUBLIN, Nov. 14, 2023 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has completed its financial restructuring, emerged from Chapter 11 following an expedited court-supervised process and completed the Irish Examinership Proceedings.

Key Points: 
  • DUBLIN, Nov. 14, 2023 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has completed its financial restructuring, emerged from Chapter 11 following an expedited court-supervised process and completed the Irish Examinership Proceedings.
  • Supported by an enhanced capital structure, Mallinckrodt will continue to focus on advancing its business across its portfolio and executing on recent and planned product launches.
  • The Company's Specialty Generics segment benefits from vertical integration and high-quality U.S.-based manufacturing plants that have supported strong growth.
  • Latham & Watkins LLP, Wachtell, Lipton, Rosen & Katz, Arthur Cox LLP, Richards, Layton & Finger PA, and Hogan Lovells US LLP served as Mallinckrodt's counsel.

Mallinckrodt plc (in Examinership) Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Adjustment, Ratio, FDA, Risk, Security (finance), United States bankruptcy court, Result, Food, Bankruptcy, Conversation, Pressure, SG, EBITDA, GAAP, Nitric oxide, Research, R, Financial condition report, Ajman Specialty General Hospital, Growth, Attention deficit hyperactivity disorder predominantly inattentive, Shanda, Near-term digital radio, Analysis, The Company, Hospital, Public, Chapter 11, Title 11, United States Code, Food and Drug Administration, Patient, ADHD, Dietary supplement, Pharmaceutical industry, Video game, Fine chemical, Cryptocurrency, Medical device, Mallinckrodt, Terlipressin

DUBLIN, Nov. 7, 2023 /PRNewswire/ -- Mallinckrodt plc (in examinership) (OTCMKTS: MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported its financial results for the third quarter ended September 29, 2023.

Key Points: 
  • Mallinckrodt's net sales in the third quarter of 2023 were $497.0 million, as compared to $465.4 million in the third quarter of 2022.
  • The Company recorded a net loss for the third quarter of $1,724.8 million, as compared to $284.9 million in the third quarter of 2022.
  • Adjusted gross profit as a percentage of sales was 66.3% for the third quarter of 2023, as compared to 66.2% for the third quarter of 2022.
  • Please see "Non-GAAP Financial Measures" included in this release for a discussion of non-GAAP measures and reconciliation of GAAP and non-GAAP financial measures for the third quarter.

Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)

Retrieved on: 
Thursday, August 31, 2023
Drug, Drug Enforcement Administration, ADHD, CII, Attention deficit hyperactivity disorder, RLD, DEA, FDA, Lisdexamfetamine, Ajman Specialty General Hospital, Generic drug, Dietary supplement, Mallinckrodt, Takeda

The FDA determined SpecGx LLC's product was bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vyvanse® Capsules of Takeda Pharmaceuticals U.S.A., Inc. (Takeda), in all seven of the RLD's approved strengths.

Key Points: 
  • The FDA determined SpecGx LLC's product was bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vyvanse® Capsules of Takeda Pharmaceuticals U.S.A., Inc. (Takeda), in all seven of the RLD's approved strengths.
  • Lisdexamfetamine Dimesylate Capsules are a federally controlled substance (CII) used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) and other indications and currently are on the FDA's drug shortage list.
  • Global net sales of Lisdexamfetamine Dimesylate exceeded $3.0 billion in Takeda's fiscal year ended March 31, 2023.
  • Upon receiving approval, which came the day following the expiration of the RLD's pediatric exclusivity, Mallinckrodt began immediate commercialization of the product.

Mallinckrodt Announces 2022 Advancing Extracorporeal Photopheresis Immunomodulation Investigator Award

Retrieved on: 
Wednesday, November 16, 2022
Quality of life, Lung transplantation, Newcastle University, SEC, Neurology, MNK, Mortality, Survival, Immunotherapy, Ajman Specialty General Hospital, CLAD, Knowledge, Nephrology, Analgesic, Medicine, Company, Immunomodulation, Rheumatology, Time, ECP, NYSE, Institute, U.S. Securities and Exchange Commission, Death, Patient, Risk, Ophthalmology, Hospital, Disability, Virulent Newcastle disease, Autoimmunity, Science, Longevity, Treatment, Biomarker, Newcastle upon Tyne Hospitals NHS Foundation Trust, Medical device, Dentistry, Pharmaceutical industry, Mallinckrodt, Transplant

DUBLIN, Nov. 16, 2022 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the recipient of 2022's Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award. Andrew Fisher, the project's principal investigator won this year's award for a project to help address significa­­nt unmet medical need by evaluating responses to extracorporeal photopheresis therapy (ECP) in chronic lung allograft dysfunction (CLAD).

Key Points: 
  • DUBLIN, Nov. 16, 2022 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the recipient of 2022's Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award.
  • Andrew Fisher, the project's principal investigator won this year's award for a project to help address significant unmet medical need by evaluating responses to extracorporeal photopheresis therapy (ECP) in chronic lung allograft dysfunction (CLAD).
  • The award, now in its fifth year, is part of Mallinckrodt's ongoing commitment to the science of immunomodulation through ECP across therapeutic applications.
  • "As a pioneer in ECP immunomodulation, Mallinckrodt is proud to support those who continue to investigate this exciting field of medicine.

Mallinckrodt Receives Approval to List on NYSE American

Retrieved on: 
Monday, October 24, 2022
U.S. Securities and Exchange Commission, The Company, SEC, MNK, Growth, Ophthalmology, NYSE, Annual report, Patient, Result, Financial condition report, Private Securities Litigation Reform Act, Conversation, NYSE American, Company, Analgesic, Analysis, Neurology, Ajman Specialty General Hospital, Immunotherapy, Rheumatology, Autoimmunity, Nephrology, Risk, Security (finance), Mallinckrodt

DUBLIN, Oct. 24, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has received approval to list its ordinary shares on NYSE American. Trading of the Company's ordinary shares on NYSE American is expected to occur under the ticker symbol "MNK" beginning on October 27, 2022. 

Key Points: 
  • Trading on NYSE American Expected to Commence Under Ticker Symbol "MNK" on October 27, 2022
    DUBLIN, Oct. 24, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has received approval to list its ordinary shares on NYSE American.
  • Trading of the Company's ordinary shares on NYSE American is expected to occur under the ticker symbol "MNK" beginning on October 27, 2022.
  • Siggi Olafsson, President and Chief Executive Officer, said, "Our listing on NYSE American marks an important step toward executing on our strategic priorities and business objectives.
  • Trading on the OTC Pink Current Market will cease concurrent with the NYSE American listing.

Slone Partners Places Patrick Genestin as Chief Business Officer at 1910 Genetics

Retrieved on: 
Thursday, October 20, 2022
People, Genetics, Hikma Pharmaceuticals, Doctor of Philosophy, Neuroscience, Biotechnology, Immunology, MBA, Artificial intelligence, Precision medicine, Technology, Automation, Infection, Ajman Specialty General Hospital, Pennsylvania State University, Probability, Drug discovery, AI, Business development, Specialty, CSL Behring, Lead, Engineering, Pharmaceutical industry, Management, Sanofi, Novartis

SOUTH RIDING, Va., Oct. 20, 2022 /PRNewswire-PRWeb/ --- Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Patrick Genestin as Chief Business Officer at 1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation, and biological automation to accelerate the design of small molecule and protein therapeutics.

Key Points: 
  • Before joining 1910 Genetics, Genestin served as Vice President of Business Development and Pipeline Strategy at Hikma Pharmaceuticals and a member of the Specialty & Generics leadership team.
  • "Patrick Genestin is an extremely accomplished, passionate, and respected business leader with a penchant for establishing strategic partnerships, attracting new investment, and stimulating growth," said Slone Partners CEO Leslie Loveless .
  • "He brings solid experience across financial, portfolio, and business development operations and is well prepared to help advance 1910 Genetics through key collaborations & partnerships."
  • "Patrick's extensive experience working with industry leaders and creating value-added deals for companies makes him an invaluable addition to the 1910 Genetics executive team," said Jen Nwankwo, Ph.D. , 1910 Genetics' Founder and Chief Executive Officer.

Mallinckrodt to Report Earnings Results for Third Quarter 2022

Retrieved on: 
Tuesday, October 18, 2022
Analgesic, Rheumatology, Neurology, Immunotherapy, Autoimmunity, Investor relations, Nephrology, Ophthalmology, Ajman Specialty General Hospital, Mallinckrodt

DUBLIN, Oct. 18, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, today announced that it will report third quarter 2022 earnings results for the period ended Sept. 30, 2022, on Tuesday, Nov. 8, 2022.

Key Points: 
  • DUBLIN, Oct. 18, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, today announced that it will report third quarter 2022 earnings results for the period ended Sept. 30, 2022, on Tuesday, Nov. 8, 2022.
  • The call can be accessed as follows:
    Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies.
  • Mallinckrodtuses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information.
  • Therefore, investors should look to the Investor Relations page of the website for important and time-critical information.

1910 Genetics Appoints Patrick Genestin as Chief Business Officer

Retrieved on: 
Tuesday, October 11, 2022
Biotechnology, Technology, Health, Pharmaceutical, Health Technology, Other Science, Research, Software, Artificial Intelligence, Genetics, Science, Genetics, Hikma Pharmaceuticals, Disease, Therapy, Neuroscience, Patient, Immunology, Multimedia, Artificial intelligence, Partnership, Technology, Infection, Ajman Specialty General Hospital, Pennsylvania State University, Probability, Drug discovery, AI, Business development, Specialty, CSL Behring, Lead, Engineering, Pharmaceutical industry, Management, Sanofi, Novartis

1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation and biological automation to accelerate the design of small molecule and protein therapeutics, today announced that it has appointed Patrick Genestin as Chief Business Officer.

Key Points: 
  • 1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation and biological automation to accelerate the design of small molecule and protein therapeutics, today announced that it has appointed Patrick Genestin as Chief Business Officer.
  • Patricks extensive experience working with industry leaders and creating value-added deals for companies makes him an invaluable addition to the 1910 Genetics executive team, said Jen Nwankwo, Ph.D., 1910 Genetics Founder and Chief Executive Officer.
  • Prior to joining 1910 Genetics, Genestin served as Vice President of Business Development and Pipeline Strategy at Hikma Pharmaceuticals and member of the Specialty & Generics leadership team.
  • I am excited to join 1910 Genetics at such a pivotal time for the company, Genestin said.

Mallinckrodt Announces Appointment of Susan Silbermann to its Board of Directors

Retrieved on: 
Thursday, October 6, 2022
U.S. Securities and Exchange Commission, The Company, Writer, NGO, SEC, Faculty of Human, Social, and Political Science, University of Cambridge, General manager, Ophthalmology, Emerging market, Vaccine, Education, Politics, Annual report, Patient, Tufts University, Commercial, IAVI, Region, Risk, Senior, Private Securities Litigation Reform Act, Infection, Social, Administration, Company, Trade, Analgesic, Neurology, Ajman Specialty General Hospital, Board, International business, Safety, Immunotherapy, Board of directors, Rheumatology, HIV-AIDS, Autoimmunity, COVID-19, Nephrology, Public health, Management, Pharmaceutical industry, Marketing, Pfizer, Biology, New York University, Mallinckrodt

DUBLIN, Oct. 6, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has appointed Susan Silbermann to its Board of Directors, effective October 5, 2022.

Key Points: 
  • DUBLIN, Oct. 6, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has appointed Susan Silbermann to its Board of Directors, effective October 5, 2022.
  • With the addition of Ms. Silbermann, the Mallinckrodt Board will expand to nine directors, eight of whom are independent.
  • "Susan is a highly respected and deeply experienced global executive in the healthcare industry, and we are pleased to welcome her to Mallinckrodt's Board," said Paul Bisaro, Chairman of the Mallinckrodt Board of Directors.
  • "I am excited to join the Mallinckrodt Board at this transformative moment for the Company," said Ms. Silbermann.